Navigation Links
Hemispherx Presents Evidence of Ampligen Synergies with Existing,Antivirals at International Avian Influenza Conference

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Hemispherx Biopharma, Inc. (AMEX: HEB), a biopharmaceutical company engaged in the clinical development of new drug entities for the treatment of pandemic disease threats, announced today a new scientific report on the activity of its experimental therapeutic Ampligen(R) in combination with approved anti-influenza agents against highly pathogenic avian influenza (HPAI), also known as bird flu.

Tamiflu resistance by newly emerging strains of HPAI has been widely reported (New Engl. Journal Medicine vol. 353: page 2667, 2005) and has provided impetus for new ways to implement an antiviral counter-attack strategy.

In in vitro studies, Ampligen(R), an experimental therapeutic, was combined with the neuraminidase inhibitors Oseltamivir, (brand name Tamiflu) and with Zanamivir (Relenza) and thereafter applied to cells in culture infected with an H5N1 strain of HPAI. Three days following infection, cell viability and synergy analyses were performed.

Both Ampligen(R) and the neuraminidase inhibitors exhibited dose responses in the inhibition of the adverse effects of HPAI on cell cultures. Moreover, the combination of Ampligen(R) with oseltamivir at doses exceeding a certain threshold showed synergistic inhibition of viral induced cell destruction, and similar synergistic results were seen with the combination of Ampligen(R) with zanamivir.

The study results are being presented at the ongoing 2nd International Conference on Avian Influenza, being held at the Pasteur Institute.

While it is widely recognized that HPAI is a major, global public health concern, existing antiviral monotherapies can rapidly lead to drug-resistant strains of virus. Therefore, the Hemispherx study was conducted to establish a potentially pivotal role for Ampligen as part of a potentially effective combination therapy. Ampligen(R) is a novel double-stranded RNA experimental thera
'"/>




Page: 1 2 3

Related medicine technology :

1. Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:8/22/2014)... Ireland , August 22, 2014 /PRNewswire/ ... and Markets ( http://www.researchandmarkets.com/research/x34qgv/global_laboratory ) has announced the ... Market 2014-2018"  report to their offering.  ... balance is an essential instrument for any ... the precise weighing of materials. It can ...
(Date:8/22/2014)...  Diplomat, the nation,s largest independent specialty pharmacy, ... in the 2014 Innovations in Specialty Pharmacy Competition, ... of the competition were announced in the August ... Diplomat was honored as a Top Innovator ... Through Diplomat University, the company has implemented a ...
(Date:8/22/2014)... , Aug. 22, 2014 Research ... "Stem Cell Research Products: Opportunities, Tools & Technologies" ... already supply stem cell research products or you wish ... essential and lucrative this market is. The authors know ... sell more effectively to scientists, to generate improved revenues ...
Breaking Medicine Technology:Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Diplomat honored as a Top Innovator by Specialty Pharmacy News 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3
... 2011 Bayer HealthCare Pharmaceuticals Inc. today ... cohort safety study offer insights into the increased risk ... a well-established risk in women who use combination oral ... Specifically, the new data provides healthcare providers with information ...
... Therapeutics today announced  the initiation of a Phase ... XMT-1001 , a novel DNA topoisomerase I inhibitor based ... in second-line gastric cancer and second-/third-line non-small cell lung ... clinical centers in the US.  The Phase 1b follows ...
Cached Medicine Technology:New Interim Data About Combination Oral Contraceptives 2New Interim Data About Combination Oral Contraceptives 3New Interim Data About Combination Oral Contraceptives 4New Interim Data About Combination Oral Contraceptives 5New Interim Data About Combination Oral Contraceptives 6Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer 2Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer 3
(Date:8/22/2014)... Va. (PRWEB) August 22, 2014 On ... Center for Medical and Health Sciences , hosting a ... area’s top influencers in government and public welfare. , ... College of Osteopathic Medicine (LUCOM) joined Liberty staff, ... and the launch of the new medical school. Classes ...
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... authentic content that is written by marketing experts for ... and affiliate links has caught the attention of Shane ... is involved with Internet marketing in any way knows ... or failure in the industry,” reports Michaels. “But even ...
(Date:8/22/2014)... 2014 Japantown Dental is excited to ... whitening technique. Air polishing is a technique used to ... teeth can be caused by a number of factors, ... internal stains. External stains include coffee, wine, tea, smoking ... certain medications, such as tetracycline, and direct trauma to ...
(Date:8/22/2014)... team has found that targeted automated alerts in ... in hospital patients with urinary catheters. In addition, ... the rate of improvement dramatically increased. , The ... urinary catheters in the first place and then ... that have not been removed within a recommended ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Natural ... Kevin Richardson to restore his own vision from legally blind ... Michaels, prompting an investigative review. , “There is a ... or contacts for everyday function, and most people just think ... to corrective eye surgery that can be pretty risky at ...
Breaking Medicine News(10 mins):Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 2Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 3Health News:Liberty University Dedicates Its New Center for Medical and Health Sciences 4Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Japantown Dental Introduces Air Polishing 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2
... Inaugural Gala, NORTH ADAMS, Mass., Nov. 14 ... today announced that it will hold,its first Roundtable meeting ... Institute, established by NPSF in May 2007, is a,think ... action for,the field of patient safety. Its goal is ...
... , Ohio -- Scientists are one step closer to ... for supporting life. , For the first time, scientists ... protein molecules to enable different functions to happen. , ... of the Proceedings of the National Academy of Sciences, ...
... your name and initials? Most people do and, as past ... other important behaviors. For example, Jack is more likely to ... is more likely to move to Philadelphia and marry Phyllis. ... it is influential enough to encourage the pursuit of name-resembling ...
... in the World Journal of Gastroenterology on November 7, ... case of gastric carcinosarcoma obtained in this part of ... Tomislav Randjelovic as surgeon and Dr. Branka Filipovic as ... his team; the anatomical and patoanatomical evaluation of macroscopic ...
... Asenapine -- a fast-,dissolving, sublingual tablet being ... and well-tolerated in patients with acute schizophrenia,according to ... of the Journal,of Clinical Psychiatry. These data were ... meeting and at the annual,congress of the European ...
... International,Isotopes Inc. (OTC Bulletin Board: INIS) is pleased ... Chief Financial Officer (CFO),effective November 13, 2007. ... 2007,as Chief Accounting Officer. Ms. McKenzie-Carter has approximately ... Previously, she served as,chief accountant for a sizeable ...
Cached Medicine News:Health News:Lucian Leape Institute Announces First Roundtable 2Health News:Lucian Leape Institute Announces First Roundtable 3Health News:Scientists get first look at how water 'lubricates' proteins 2Health News:What's in a name? Initials linked to success, study shows 2Health News:Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia 2Health News:Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia 3Health News:Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia 4Health News:Laurie McKenzie-Carter Named Chief Financial Officer of International Isotopes Inc. 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: